Virtual Exhibit Hall Home
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on novel oncology therapeutics. ELZONRISÒ (tagraxofusp), a CD123-directed cytotoxin, is FDA-approved for treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ELZONRIS is in clinical trials for additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Pipeline candidates include: felezonexor (SL-801; XPO1 inhibitor; Phase 1 in advanced solid tumors), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in GBM completed), and SL-901 (novel kinase inhibitor; IND-enabling studies ongoing).
ELZONRIS US Full Prescribing Information